BBT 1006

BAT1006 is a monoclonal antibody targeting HER2 extracellular domain II with enhanced antibody-dependent cell-mediated cytotoxicity (ADCC) for the study of HER2-positive locally advanced/metastatic solid tumors. BAT1006 has an approximately 5-fold enhanced ADCC effect compared to pertuzumab and exhibits potent anti-tumor activity in the HER2-positive Calu-3 xenograft mouse model[1].

12352203

EGFR

JAK/STAT Signaling; Protein Tyrosine Kinase/RTK

Cancer-Kinase/protease

Cancer

[BAT1006]

[1]Xingxing Mei, et al. Abstract CT189: A phase I study of BAT1006, a novel anti-HER2 antibody, in patients with locally advanced/metastatic solid tumors. Cancer research. Cancer Res (2023) 83 (8_Supplement) : CT189.

Room temperature

http://file.medchemexpress.com/batch_PDF/HY-P991233/

Inhibitory Antibodies

Phase 2